S&P Futures
4,020.25 +15.50 (+0.39%) Dow Futures
32,241.00 +82.00 (+0.25%) Nasdaq Futures
12,321.25 +76.50 (+0.62%) Russell 2000 Futures
1,790.60 +8.20 (+0.46%) Crude Oil
113.80 -0.40 (-0.35%) Gold
1,824.40 +10.40 (+0.57%)
Novo Nordisk A/S (NOVC.DE)
Chart Events
Performance Outlook
| Previous Close | 102.16 |
| Open | 99.54 |
| Bid | 98.54 x 13500 |
| Ask | 98.85 x 54600 |
| Day's Range | 98.33 - 101.26 |
| 52 Week Range | 64.48 - 111.74 |
| Volume | |
| Avg. Volume | 24,585 |
| Market Cap | 250.815B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 46.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Investor's Business Daily
Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster
The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.
- GlobeNewswire
Novo Nordisk A/S: Share repurchase programme
Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate
- Zacks
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
